145 related articles for article (PubMed ID: 21143510)
1. Von Willebrand factor and fibrinolytic parameters during the desmopressin test in patients with Cushing's disease.
Pecori Giraldi F; Ambrogio AG; Fatti LM; Rubini V; Cozzi G; Scacchi M; Federici AB; Cavagnini F
Br J Clin Pharmacol; 2011 Jan; 71(1):132-6. PubMed ID: 21143510
[TBL] [Abstract][Full Text] [Related]
2. Assessment of cortisol and ACTH responses to the desmopressin test in patients with Cushing's syndrome and simple obesity.
Tsagarakis S; Vasiliou V; Kokkoris P; Stavropoulos G; Thalassinos N
Clin Endocrinol (Oxf); 1999 Oct; 51(4):473-7. PubMed ID: 10583315
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma.
Ambrosi B; Sartorio A; Pizzocaro A; Passini E; Bottasso B; Federici A
Exp Clin Endocrinol Diabetes; 2000; 108(4):294-8. PubMed ID: 10961361
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus.
Grant MB; Fitzgerald C; Guay C; Lottenberg R
Metabolism; 1989 Sep; 38(9):901-7. PubMed ID: 2505017
[TBL] [Abstract][Full Text] [Related]
5. Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.
Wieczorek I; Ludlam CA; MacGregor IR
Blood Coagul Fibrinolysis; 1994 Jun; 5(3):329-34. PubMed ID: 8075304
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of Cushing's disease preceded by the reappearance of ACTH and cortisol responses to desmopressin test.
Dall'Asta C; Barbetta L; Bonavina L; Beck-Peccoz P; Ambrosi B
Pituitary; 2004; 7(3):183-188. PubMed ID: 16328567
[TBL] [Abstract][Full Text] [Related]
7. The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies.
van de Kar NC; van Hinsbergh VW; Brommer EJ; Monnens LA
Pediatr Res; 1994 Aug; 36(2):257-64. PubMed ID: 7970942
[TBL] [Abstract][Full Text] [Related]
8. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
[TBL] [Abstract][Full Text] [Related]
9. Blood fibrinolysis and the response to desmopressin in glomerulonephritis.
Brommer EJ; Van den Wall Bake AW; Dooijewaard G; van Loon BJ; Emeis JJ; Weening JJ
Thromb Haemost; 1994 Jan; 71(1):19-25. PubMed ID: 8165642
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man.
Labinjoh C; Newby DE; Dawson P; Johnston NR; Ludlam CA; Boon NA; Webb DJ
Cardiovasc Res; 2000 Sep; 47(4):707-14. PubMed ID: 10974219
[TBL] [Abstract][Full Text] [Related]
11. Desmopressin and hexarelin tests in alcohol-induced pseudo-Cushing's syndrome.
Coiro V; Volpi R; Capretti L; Caffarri G; Chiodera P
J Intern Med; 2000 Jun; 247(6):667-73. PubMed ID: 10886488
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of the desmopressin test in the postoperative evaluation of patients with Cushing's disease.
Colombo P; Dall'Asta C; Barbetta L; Re T; Passini E; Faglia G; Ambrosi B
Eur J Endocrinol; 2000 Aug; 143(2):227-34. PubMed ID: 10913942
[TBL] [Abstract][Full Text] [Related]
13. Effect of desmopressin on ACTH and cortisol secretion in states of ACTH excess.
Colombo P; Passini E; Re T; Faglia G; Ambrosi B
Clin Endocrinol (Oxf); 1997 Jun; 46(6):661-8. PubMed ID: 9274696
[TBL] [Abstract][Full Text] [Related]
14. Local and systemic effects of intra-arterial desmopressin in healthy volunteers and patients with type 3 von Willebrand disease. Role of interleukin-6.
Newby DE; Stewart A; Witherow FN; Grieve S; Dawson P; Fox KA; Webb DJ; Ludlam CA
Thromb Haemost; 2000 Aug; 84(2):195-203. PubMed ID: 10959689
[TBL] [Abstract][Full Text] [Related]
15. Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity.
Li Y; Chen H; Tan J; Wang X; Liang H; Sun X
Eur J Clin Invest; 1998 Dec; 28(12):1050-4. PubMed ID: 9893018
[TBL] [Abstract][Full Text] [Related]
16. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state.
Patrassi GM; Sartori MT; Viero ML; Scarano L; Boscaro M; Girolami A
Blood Coagul Fibrinolysis; 1992 Dec; 3(6):789-93. PubMed ID: 1489900
[TBL] [Abstract][Full Text] [Related]
17. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
Sultan Y; Loyer F; Venot A
Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100
[TBL] [Abstract][Full Text] [Related]
18. The limited value of the desmopressin test in the diagnostic approach to Cushing's syndrome.
Terzolo M; Reimondo G; Alì A; Borretta G; Cesario F; Pia A; Paccotti P; Angeli A
Clin Endocrinol (Oxf); 2001 May; 54(5):609-16. PubMed ID: 11380491
[TBL] [Abstract][Full Text] [Related]
19. Role for postoperative cortisol response to desmopressin in predicting the risk for recurrent Cushing's disease.
Romanholi DJ; Machado MC; Pereira CC; Danilovic DS; Pereira MA; Cescato VA; Cunha Neto MB; Musolino NR; de Mendonça BB; Salgado LR
Clin Endocrinol (Oxf); 2008 Jul; 69(1):117-22. PubMed ID: 18182093
[TBL] [Abstract][Full Text] [Related]
20. The application of the combined corticotropin-releasing hormone plus desmopressin stimulation during petrosal sinus sampling is both sensitive and specific in differentiating patients with Cushing's disease from patients with the occult ectopic adrenocorticotropin syndrome.
Tsagarakis S; Vassiliadi D; Kaskarelis IS; Komninos J; Souvatzoglou E; Thalassinos N
J Clin Endocrinol Metab; 2007 Jun; 92(6):2080-6. PubMed ID: 17356045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
